Conference milestone

Obesity treatment is becoming a portfolio, not a product. Lilly’s EASD lineup shows what comes next

Cardiovascular AI is getting better. That does not mean it is getting fairer

Virtual reality may solve one of cardiac imaging’s most overlooked barriers

AI can find hidden heart disease in routine ECGs. The policy challenge is deciding who gets fast-tracked

Do patients need maximum-dose tirzepatide forever? New data suggest a middle ground

Ovarian Cancer May Finally Have a Way to Drug p53

Bayer’s ESC 2026 programme puts the heart-kidney axis centre stage. Disease silos are starting to look obsolete

GLP-1 drugs can reduce adolescent obesity. Who will pay for years of treatment?

Alzheimer’s Pill Has Finished the Trial. Evidence Has Not.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
